EUVIMEDEUVIMED entdecken
Crossref

A Retrospective Comparison of Daptomycin Thrice-Weekly versus Q48H Dosing in Hemodialysis Patients with Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia

Katie L Axford, Dane L Shiltz

Advances in Pharmacology and Pharmacy · 2014

DOI: 10.13189/app.2014.020101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Pharmacology and Pharmacy, 2014. Verfasst von Katie L Axford und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Axford, K. L., & Shiltz, D. L. (2014). A Retrospective Comparison of Daptomycin Thrice-Weekly versus Q48H Dosing in Hemodialysis Patients with Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia. Advances in Pharmacology and Pharmacy. https://doi.org/10.13189/app.2014.020101

Vancouver

Axford KL, Shiltz DL. A Retrospective Comparison of Daptomycin Thrice-Weekly versus Q48H Dosing in Hemodialysis Patients with Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia. Advances in Pharmacology and Pharmacy. 2014. doi:10.13189/app.2014.020101

BibTeX
@article{Axford2014,
  author = {Axford, Katie L and Shiltz, Dane L},
  title = {A Retrospective Comparison of Daptomycin Thrice-Weekly versus Q48H Dosing in Hemodialysis Patients with Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia},
  journal = {Advances in Pharmacology and Pharmacy},
  year = {2014},
  doi = {10.13189/app.2014.020101}
}
Kostenlos starten →